These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 12497205

  • 21. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
    Baguley BC, Zhuang L, Kestell P.
    Oncol Res; 1997; 9(2):55-60. PubMed ID: 9167186
    [Abstract] [Full Text] [Related]

  • 22. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
    Philpott M, Baguley BC, Ching LM.
    Cancer Chemother Pharmacol; 1995; 36(2):143-8. PubMed ID: 7767951
    [Abstract] [Full Text] [Related]

  • 23. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Woon ST, Zwain S, Schooltink MA, Newth AL, Baguley BC, Ching LM.
    Eur J Cancer; 2003 May; 39(8):1176-83. PubMed ID: 12736120
    [Abstract] [Full Text] [Related]

  • 24. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
    Zhao L, Ching LM, Kestell P, Baguley BC.
    Br J Cancer; 2002 Aug 12; 87(4):465-70. PubMed ID: 12177785
    [Abstract] [Full Text] [Related]

  • 25. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
    Ching LM, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD.
    Br J Cancer; 1998 Aug 12; 78(3):336-43. PubMed ID: 9703279
    [Abstract] [Full Text] [Related]

  • 26. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
    Zhou SF, Tingle MD, Kestell P, Paxton JW.
    Xenobiotica; 2002 Feb 12; 32(2):87-107. PubMed ID: 11868972
    [Abstract] [Full Text] [Related]

  • 27. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
    Chung F, Wang LC, Kestell P, Baguley BC, Ching LM.
    Cancer Chemother Pharmacol; 2004 May 12; 53(5):377-83. PubMed ID: 15060740
    [Abstract] [Full Text] [Related]

  • 28. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
    Bellnier DA, Gollnick SO, Camacho SH, Greco WR, Cheney RT.
    Cancer Res; 2003 Nov 15; 63(22):7584-90. PubMed ID: 14633671
    [Abstract] [Full Text] [Related]

  • 29. Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.
    Liu JJ, Ching LM, Goldthorpe M, Sutherland R, Baguley BC, Kirker JA, McKeage MJ.
    Cancer Chemother Pharmacol; 2007 Apr 15; 59(5):661-9. PubMed ID: 16944150
    [Abstract] [Full Text] [Related]

  • 30. The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
    Philpott M, Ching LM, Baguley BC.
    Eur J Cancer; 2001 Oct 15; 37(15):1930-7. PubMed ID: 11576850
    [Abstract] [Full Text] [Related]

  • 31. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M, Spernyak JA, Mazurchuk R, Camacho SH, Oseroff AR, Cheney RT, Bellnier DA.
    Clin Cancer Res; 2005 Jun 01; 11(11):4241-50. PubMed ID: 15930363
    [Abstract] [Full Text] [Related]

  • 32. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
    Zhou S, Kestell P, Tingle MD, Ching LM, Paxton JW.
    Cancer Chemother Pharmacol; 2001 Jun 01; 47(6):541-4. PubMed ID: 11459209
    [Abstract] [Full Text] [Related]

  • 33. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
    Chung F, Liu J, Ching LM, Baguley BC.
    Cancer Chemother Pharmacol; 2008 Mar 01; 61(3):497-502. PubMed ID: 17473922
    [Abstract] [Full Text] [Related]

  • 34. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cao Z, Baguley BC, Ching LM.
    Cancer Res; 2001 Feb 15; 61(4):1517-21. PubMed ID: 11245459
    [Abstract] [Full Text] [Related]

  • 35. DMXAA: an antivascular agent with multiple host responses.
    Baguley BC, Ching LM.
    Int J Radiat Oncol Biol Phys; 2002 Dec 01; 54(5):1503-11. PubMed ID: 12459378
    [Abstract] [Full Text] [Related]

  • 36. Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.
    Wang LC, Ching LM, Paxton JW, Kestell P, Sutherland R, Zhuang L, Baguley BC.
    Invest New Drugs; 2009 Jun 01; 27(3):280-4. PubMed ID: 18696010
    [Abstract] [Full Text] [Related]

  • 37. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH.
    Cancer Res; 1999 Aug 15; 59(16):3998-4003. PubMed ID: 10463598
    [Abstract] [Full Text] [Related]

  • 38. Effect of tumour growth on the macrophage response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
    Ching LM, Joseph WR, Baguley BC.
    Anticancer Res; 1993 Aug 15; 13(6A):2069-75. PubMed ID: 8297115
    [Abstract] [Full Text] [Related]

  • 39. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
    Breidahl T, Nielsen FU, Stødkilde-Jørgensen H, Maxwell RJ, Horsman MR.
    Acta Oncol; 2006 Aug 15; 45(3):306-16. PubMed ID: 16644574
    [Abstract] [Full Text] [Related]

  • 40. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
    Yung R, Seyfoddin V, Guise C, Tijono S, McGregor A, Connor B, Ching LM.
    Cancer Chemother Pharmacol; 2014 Mar 15; 73(3):639-49. PubMed ID: 24477604
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.